Abstract:HomeCirculation ResearchVol. 131, No. 12Prohibiting MG53 Phosphorylation Optimizes its Therapeutic Potential in Diabetes Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBProhibiting MG53 Phosphorylation Optimizes its Therapeutic Potential in Diabetes Duane D. Hall, Qian Shi and Long-Sheng Song Duane D. HallDuane D. Hall https://orcid.org/0000-0003-2228-0966 Division of Cardiovascular Medicine, Department of Internal Medicine, Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa. , Qian ShiQian Shi https://orcid.org/0000-0003-2634-9553 Division of Cardiovascular Medicine, Department of Internal Medicine, Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa. and Long-Sheng SongLong-Sheng Song Correspondence to: Long-Sheng Song, MD, FAHA, FISHR Department of Internal Medicine, Carver College of Medicine, University of Iowa, 285 Newton Rd, Iowa City, IA 52242, Email E-mail Address: [email protected] https://orcid.org/0000-0002-6035-8106 Division of Cardiovascular Medicine, Department of Internal Medicine, Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa. Originally published1 Dec 2022https://doi.org/10.1161/CIRCRESAHA.122.322132Circulation Research. 2022;131:977–979This article is a commentary on the followingBlocking MG53S255 Phosphorylation Protects Diabetic Heart From Ischemic InjuryOrgan damage from diabetes drastically reduces patient quality of life and places an enormous burden on healthcare systems across the globe. The heart is particularly affected in type 2 diabetic patients with most deaths attributed to cardiovascular complications. During diabetes, heart function is impaired with compromised cellular signaling, making it more susceptible to additional insults such as myocardial infarction and ischemia/reperfusion (I/R) injury.1 Diabetes is a risk factor for ischemic heart disease as evidenced by a 2- to 4-fold increase in the incidence of myocardial infarction in patients with diabetes compared to those without diabetes. Understanding how diabetes sets the stage for increased myocardial damage has important clinical implications.Article, see p 962The heart is an insulin responsive organ.1 Cardiac insulin signaling mediates cellular homeostasis via control of protein synthesis, substrate utilization, and cell survival. In a healthy heart, insulin activates phosphoinositide-3-kinase-Akt signaling and promotes GLUT4 translocation to the cell surface to facilitate glucose transport. Under normal conditions, the heart primarily uses lipid as a fuel via aerobic metabolism. However, during ischemia, the heart shifts its energy production from aerobic metabolism to anaerobic metabolism, in which anaerobic glycolysis becomes important in the preservation of myocardial viability. The impaired ability to utilize glucose due to blunted insulin responsiveness, that is, insulin resistance, contributes to the pathology of the diabetic heart.MG53, also known as TRIM72, has been shown to regulate insulin sensitivity in skeletal and cardiac myocytes. MG53 is highly enriched in striated muscle and promotes the ubiquitination and degradation of insulin receptor (IR)α/β and insulin receptor substrate 1 (IRS1).2,3 The E3 ubiquitin ligase function of MG53 localizes to its N-terminus and within its tripartite motif consisting of RING, B-box, and coiled-coil sequences. A cystine to alanine mutation at residue 14 (C14A) in the RING domain of MG53 blocks its E3 ligase activity and prevents ubiquitination of its substrates including IR α/β and IRS1.2,3 The function of the central and C-terminal regions of MG53, on the contrary, acts to repair damaged membranes. Adult differentiated myocytes have limited regenerative capacity and therefore rely on effective membrane repair mechanisms for cell survival. Upon membrane rupture and exposure to the oxidizing extracellular environment, MG53 oligomerizes through interchain Cystine 242 disulfide bond formation and translocates to membrane rupture sites with bound vesicles to facilitate membrane repair using its PRY/SPRY domain.4 How the separate degradation versus reparative activities of MG53 contribute to its overall function has yet to be fully understood. Genetic manipulation of MG53 suggests its membrane repair function dominates under basal conditions. MG53 null mice have a progressive skeletal myopathy and exhibit diminished myocyte membrane repair after exercise.4 However, cardiomyocyte transverse-tubule membrane integrity remains intact in the absence of MG53 at baseline and over a long period of time. Under mechanic pressure overload stress, MG53 deletion leads to more severe cardiac dysfunction as a result of exacerbated T-tubule degeneration, likely due to the loss of MG53-mediated membrane repair function.5Interestingly, MG53 is not locally restrained to the damaged myocyte from where it is produced but is also effectively released into the circulation during exercise and pathological stress including myocardial infarction and I/R injury.6,7 Several studies have now demonstrated that circulating MG53 can act as an important systemic myokine for recruitment to sites of organ damage. Intravenous injection of recombinant human MG53 (rhMG53) reduces the pathological consequences from muscular dystrophy and kidney injury, among other models.8,9 In a similar fashion, transgenic expression of serum-targeted MG53 in MG53 null mice demonstrates its systemic myokine function is distinct from its intracellular role10 and can even cross the blood-brain barrier to facilitate recovery from neuronal I/R injury.11Given its ability to ubiquitinate insulin signaling molecules for their degradation, there is growing interest into whether intracellular or systemic MG53 plays a role in the pathogenesis of diabetes. MG53 deleted mice are protected against high-fat diet-induced hyperglycemia, hyperlipidemia, and insulin insensitivity.2,3 In parallel, insulin stimulation of MG53 knockout skeletal myocytes results in higher levels of total and phosho-IRS1 and phospho-Akt compared to wildtype myocytes suggesting insulin signaling is elevated in MG53 null muscle through reduced MG53-dependent ubiquitination. On the other hand, insulin triggers MG53 secretion from skeletal and cardiac tissue both in normal and diabetic animals.7,12 The consequences of circulating MG53 on diabetic outcomes apart from its intracellular role has begun to be explored but remains a matter of debate.12Mechanistic studies that differentiate between the positive actions of MG53 on membrane repair from its negative effects on insulin signaling would be expected to shed light into the function of MG53 in the context of diabetes and diabetic cardiomyopathy. Xiao and colleagues wondered if the E3 ligase function of MG53 could be manifested more clearly in diabetic animals subjected to myocardial ischemic events. Earlier this year, the Xiao group found that E3 ligase deficient knock-in mutation of MG53 (C14A) or systemic administration of rhMG53-C14A protein is more effective at protecting mice from myocardial infarction and I/R damage than wildtype (WT) MG53 controls,13 supporting the idea MG53 ligase activity is detrimental in diabetic animals upon organ damage.In this issue, Lv et al14 extended their findings into MG53 ligase function by exploring whether endogenous kinases act to shift the balance between MG53 substrate ubiquitination and membrane healing activities (Figure). By performing mass spectrometry analysis on MG53 immunoprecipitated from skeletal myocytes and heterologously expressing HEK cells, the residue Serine 255 was found to be phosphorylated in both groups and among 5 phosphosites in the muscle expressed protein. Of the candidate-phosphorylated residues, only mutation of Serine 255 to alanine (S255A), which prevents phosphorylation of the residue, blocked the ubiquitination and downregulation of IRS1 and IRβ in cultured neonatal rat ventricular myocytes and immortalized C2C12 myotube cells. Mimicking phosphorylation of Serine 255 by aspartate and glutamate substitution had no effect on IRS1 and IRβ downregulation suggesting Serine 255 is basally phosphorylated. Serine 255 appears to mediate MG53 recognition of its substrates as MG53 S255A mutants fail to interact with either IRS1 or IRα.Download figureDownload PowerPointFigure. Schematic diagram showing the dual paradoxical functions of MG53 protein (left), and how modifications of key residues transform MG53 into a single purposed therapeutic (right).Prediction analyses suggests Serine 255 is a GSK3β consensus site. Using skeletal muscle lysates, GSK3β was found to reciprocally co-immunoprecipitate with MG53. Furthermore, inhibition of GSK3 blunted MG53 phosphorylation at Serine 255 and MG53-S255A mutation blocked the ubiquitination of IRS1 in response to GSK3 overexpression. These results establish that a mechanistic feedback loop exists between insulin sensitivity, GSK3β, and MG53. Examination of cardiac tissue from several rodent and nonhuman primate models of metabolic syndrome revealed that IRS1, IRβ, and inhibitory GSK3β phosphorylation levels are decreased in parallel with increased MG53 phosphorylation at Serine 255. Furthermore, the S255A mutation does not affect the membrane repair function of MG53. Overexpression of MG53-WT and MG53-S255A constructs equally protected neonatal rat ventricular myocytes against hypoxia-induced cell death. Exogenously applied rhMG53-WT and rhMG53-S255A protein both attenuated hypoxic LDH release and cell death as well as accelerated the healing of detergent-ruptured myocyte membranes.Cumulatively, these findings suggested MG53 phosphorylation at Serine 255 is a pathologically relevant modification. To investigate the translational potential of MG53, the authors studied short- and long-term consequences from myocardial infarction and I/R in spontaneously diabetic db/db animals treated with rhMG53-WT or rhMG53-S255A. In each scenario, rhMG53-S255A was found to be more effective than rhMG53-WT at improving cardiac outcomes from ischemic and reperfusion injury.In summary, the study by Lv et al14 provides new insights into how MG53 targets protein substrates for ubiquitination. In diabetic heart, GSK3-dependent phosphorylation of MG53 at Serine 255 increases MG53 recognition, ubiquitination, and degradation of critical insulin signaling pathway proteins, contributing to insulin resistance and increased susceptibility to ischemic injury. Preventing Serine 255 phosphorylation by GSK3 potentiates the beneficial effect of MG53 in limiting the degree of cardiac damage from ischemic events in the context of metabolic disease. It will be important for future studies to determine whether other MG53 ubiquitinated substrates in addition to IRs and IRS1 contribute to end-organ damage. Also important to address is whether Serine 255 directly affects the E3 ligase activity of MG53 or only prevents MG53 from finding its substrates. Another open question is whether Serine 255 phosphorylation also contributes to self-dimerization and/or membrane fusion in addition to its effects on substrate ubiquitination.Article InformationDisclosures None.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 979.Correspondence to: Long-Sheng Song, MD, FAHA, FISHR Department of Internal Medicine, Carver College of Medicine, University of Iowa, 285 Newton Rd, Iowa City, IA 52242, Email long-sheng-song@uiowa.eduReferences1. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure.Circ Res. 2021; 128:1487–1513. doi: 10.1161/CIRCRESAHA.121.318241LinkGoogle Scholar2. Song R, Peng W, Zhang Y, Lv F, Wu HK, Guo J, Cao Y, Pi Y, Zhang X, Jin L, et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders.Nature. 2013; 494:375–379. doi: 10.1038/nature11834CrossrefMedlineGoogle Scholar3. Yi JS, Park JS, Ham YM, Nguyen N, Lee NR, Hong J, Kim BW, Lee H, Lee CS, Jeong BC, et al. MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling.Nat Commun. 2013; 4:2354. doi: 10.1038/ncomms3354CrossrefMedlineGoogle Scholar4. Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, Ko JK, Lin P, Thornton A, Zhao X, et al. MG53 nucleates assembly of cell membrane repair machinery.Nat Cell Biol. 2009; 11:56–64. doi: 10.1038/ncb1812CrossrefMedlineGoogle Scholar5. Zhang C, Chen B, Wang Y, Guo A, Tang Y, Khataei T, Shi Y, Kutschke WJ, Zimmerman K, Weiss RM, et al. MG53 is dispensable for T-tubule maturation but critical for maintaining T-tubule integrity following cardiac stress.J Mol Cell Cardiol. 2017; 112:123–130. doi: 10.1016/j.yjmcc.2017.08.007CrossrefMedlineGoogle Scholar6. Liu J, Zhu H, Zheng Y, Xu Z, Li L, Tan T, Park KH, Hou J, Zhang C, Li D, et al. Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury.J Mol Cell Cardiol. 2015; 80:10–19. doi: 10.1016/j.yjmcc.2014.12.010CrossrefMedlineGoogle Scholar7. Wu HK, Zhang Y, Cao CM, Hu X, Fang M, Yao Y, Jin L, Chen G, Jiang P, Zhang S, et al. Glucose-sensitive myokine/cardiokine mg53 regulates systemic insulin response and metabolic homeostasis.Circulation. 2019; 139:901–914. doi: 10.1161/CIRCULATIONAHA.118.037216LinkGoogle Scholar8. Duann P, Li H, Lin P, Tan T, Wang Z, Chen K, Zhou X, Gumpper K, Zhu H, Ludwig T, et al. MG53-mediated cell membrane repair protects against acute kidney injury.Sci Transl Med. 2015; 7:279ra–27236. doi: 10.1126/scitranslmed.3010755CrossrefGoogle Scholar9. Weisleder N, Takizawa N, Lin P, Wang X, Cao C, Zhang Y, Tan T, Ferrante C, Zhu H, Chen PJ, et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy.Sci Transl Med. 2012; 4:139ra–13185. doi: 10.1126/scitranslmed.3003921CrossrefGoogle Scholar10. Bian Z, Wang Q, Zhou X, Tan T, Park KH, Kramer HF, McDougal A, Laping NJ, Kumar S, Adesanya TMA, et al. Sustained elevation of MG53 in the bloodstream increases tissue regenerative capacity without compromising metabolic function.Nat Commun. 2019; 10:4659. doi: 10.1038/s41467-019-12483-0CrossrefMedlineGoogle Scholar11. Yao Y, Zhang B, Zhu H, Li H, Han Y, Chen K, Wang Z, Zeng J, Liu Y, Wang X, et al. MG53 permeates through blood-brain barrier to protect ischemic brain injury.Oncotarget. 2016; 7:22474–22485. doi: 10.18632/oncotarget.7965CrossrefMedlineGoogle Scholar12. Wang Q, Bian Z, Jiang Q, Wang X, Zhou X, Park KH, Hsueh W, Whitson BA, Haggard E, Li H, et al. MG53 does not manifest the development of diabetes in db/db mice.Diabetes. 2020; 69:1052–1064. doi: 10.2337/db19-0807CrossrefMedlineGoogle Scholar13. Feng H, Shen H, Robeson MJ, Wu YH, Wu HK, Chen GJ, Zhang S, Xie P, Jin L, He Y, et al. MG53 E3 ligase-dead mutant protects diabetic hearts from acute ischemic/reperfusion injury and ameliorates diet-induced cardiometabolic damage.Diabetes. 2022; 71:298–314. doi: 10.2337/db21-0322CrossrefMedlineGoogle Scholar14. Lv F, Wang Y, Shan D, Guo S, Chen GJ, Jin L, Zheng W, Feng H, Zeng X, Zhang S, et al. Breaking GSK3β-MG53S255 phosphorylation-insulin resistance vicious cycle to treat diabetes associated acute myocardial injury.Circ Res. 2022Google Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesBlocking MG53S255 Phosphorylation Protects Diabetic Heart From Ischemic InjuryFengxiang Lv, et al. Circulation Research. 2022;131:962-976 December 2, 2022Vol 131, Issue 12 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.122.322132PMID: 36454851 Originally publishedDecember 1, 2022 PDF download Advertisement

Abstract:HomeCirculationVol. 139, No. 7Secreted MG53 From Striated Muscle Impairs Systemic Insulin Sensitivity Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBSecreted MG53 From Striated Muscle Impairs Systemic Insulin Sensitivity Lenan Zhuang, PhD, Rhonda Bassel-Duby, PhD and Eric N. Olson, PhD Lenan ZhuangLenan Zhuang Department of Molecular Biology and Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas. Search for more papers by this author , Rhonda Bassel-DubyRhonda Bassel-Duby Department of Molecular Biology and Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas. Search for more papers by this author and Eric N. OlsonEric N. Olson Eric N. Olson, PhD, UT Southwestern Medical Center, Department of Molecular Biology, 6000 Harry Hines Blvd, Dallas, TX 75390-9148. Email E-mail Address: [email protected] Department of Molecular Biology and Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas. Search for more papers by this author Originally published11 Feb 2019https://doi.org/10.1161/CIRCULATIONAHA.118.038387Circulation. 2019;139:915–917This article is a commentary on the followingGlucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic HomeostasisArticle, see p 901Diabetes mellitus is 1 of the most prevalent health challenges worldwide, affecting >422 million people. In the United States alone, >30 million people were diagnosed with diabetes mellitus in 2015, and this number is predicted to double by 2030.1 More than 1 of every 3 adults in the United States has prediabetes, indicated by elevated blood glucose levels but below those of full-blown diabetes mellitus. Prediabetic patients are generally insulin-resistant, meaning that their muscle, fat, and liver cells are resistant to glucose uptake from the blood. Despite decades of research, we still do not fully understand the underlying causes of insulin resistance and prediabetes.Skeletal muscle is the major site of glucose uptake in humans.2 Maintaining the integrity of the insulin signaling pathway is essential for normal insulin-mediated glucose uptake in muscle. Skeletal muscle participates in systemic metabolism not only by taking up glucose, but also by sending messengers, such as secreted myokines, to communicate with other tissues. Like skeletal muscle, the heart also secretes myokines, called cardiokines.3 Secretome analysis of exercised muscle in humans and rodents previously led to the discovery of a number of myokines that were shown to have beneficial effects on body metabolism.4 Indeed, many of the identified myokines have been shown to be involved in various processes of exercise adaptation, muscle growth, and regulation of whole-body glucose/lipid metabolism. The existence of myokines and cardiokines has enhanced our understanding of how muscles communicate with other tissues such as adipose tissue, liver, bone, and brain to regulate whole-body metabolism. The list of new myokines is continuously increasing, and some are promising targets for the treatment of metabolic disorders, although their physiological actions remain largely unexplored.Skeletal muscle insulin resistance is recognized as the primary defect in patients with type 2 diabetes mellitus (T2D).5 However, the etiologic factors causing muscle insulin resistance remain unclear. It is also unknown whether diabetic muscle communicates with other tissues to promote systemic metabolic disorders. It is plausible that myokines or cardiokines secreted by diseased muscle might contribute to the systemic diabetic state. Similar to exercise-induced myokines that elicit a beneficial effect, myokines secreted by diabetic muscle may drive the pathogenesis of the disease, thereby impairing systemic metabolism. Understanding both the beneficial and deleterious functions of myokines in regulating systemic metabolism may help identify druggable targets for future treatment of insulin resistance and T2D.In this issue of Circulation, Wu et al6 report the discovery of a novel myokine, mitsugumin 53 (MG53), which impairs whole-body insulin sensitivity, further supporting the complex role of muscle as an endocrine tissue in regulating systemic metabolism. MG53 is expressed predominantly in cardiac and skeletal muscle. Unexpectedly, it was first identified as a muscle-specific E3 ubiquitin ligase involved in the repair of membrane damage.7 Subsequently, Song et al8 reported that intracellular MG53 targets the insulin receptor (IR) and IR substrate 1, for ubiquitination and degradation, thereby controlling insulin signaling in skeletal muscle. In the present study, Wu et al show for the first time that MG53 is secreted from perfused striated muscle and that the levels of circulating MG53 are elevated by glucose or insulin stimulation. The authors confirm that the secretion of MG53 is regulated by Ca2+ and the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) binding protein–dependent secretory pathway. By measuring circulating MG53 levels and metabolic parameters in diabetic rodents and humans, the authors found that circulating MG53 levels directly correlated with hyperglycemia and hyperinsulinemia. These findings indicate that circulating MG53 may serve as a biomarker for insulin resistance and T2D.To elevate levels of circulating MG53 in the body, transgenic mice that overexpress MG53 in the heart (MG53 h-TG) were developed. As early as 1 week of age, the MG53 h-TG mice showed a 1.5-fold elevation in circulating MG53 along with increased levels of blood glucose and insulin, without a significant change in body weight. By 4 months of age, MG53 h-TG mice exhibited moderate glucose and insulin intolerance. It is striking that, by 7 months of age, MG53 h-TG mice on a normal diet showed severe obesity and the onset of metabolic syndrome. More notably, intravenous administration of MG53 protein in 8- to 10-week-old wild-type mice impaired whole-body insulin sensitivity, which supports the hypothesis that circulating MG53 acts as a disease-causing factor, directly attenuating the insulin response systemically. It is interesting to note that the ablation of blood MG53 by antibody neutralization decreased blood glucose and promoted insulin sensitivity in diabetic mice. However, this improvement is not sufficiently robust to serve as a treatment for T2D. In diabetic patients and mice, it was reported that the expression of MG53 was increased in muscle tissue.8,9 Therefore, both intracellular and secreted MG53 are increased in the diabetic state. It can be speculated that the low efficacy of MG53 monoclonal antibodies may indicate that targeting only circulating MG53 is not sufficient to restore the insulin sensitivity produced by both intracellular and secreted MG53. Thus, targeting both circulating MG53 and intracellular MG53 would likely be necessary for an effective strategy for treatment of T2D.Mechanistically, the authors identified the extracellular domain (ECD) of the IR as a binding site for circulating MG53. It is important to note that the affinity of MG53 binding to the IR ECD is high (KD=8.0 nmol/L). Plus, the concentration of serum MG53 in diabetic rats measured by ELISA is ≈3 to 8 nmol/L. These data indicate that circulating MG53 directly binds to the IR ECD at nanomolar concentrations in the diabetic state. The authors specifically showed that the C-terminal domain of MG53 is important, but the RING (Really Interesting New Gene) domain, which is the E3 ubiquitin ligase catalytic domain of MG53, is dispensable for the interaction between MG53 and IR ECD. These data indicate that, in contrast to intracellular MG53, the actions of extracellular MG53 on the IR are independent of its E3 ubiquitin ligase enzyme activity. It is surprising that, although the affinity of MG53 binding to the IR ECD is higher than that of insulin (KD=28.0 nmol/L), the extracellular MG53 binding to the IR does not interrupt the binding of insulin. The authors commented that circulating MG53 may act as an allosteric, but not a competitive, blocker of IR. The binding of MG53 to the IR might impair the phosphorylation and activation of IR downstream of insulin binding, but this was not addressed. The underlying mechanism whereby extracellular MG53 blocks insulin signaling needs further investigation.This study revealed the unexpected secretion of MG53 from diabetic muscle, providing a new avenue for exploration of the role of MG53 in regulating whole-body metabolism. However, it raises additional questions to be answered. For example, the mechanism whereby high glucose and insulin induce the secretion of MG53 remains unclear. Of note, MG53 protein is much larger than other previously reported myokines. Whether the secreted MG53 is located inside exosomes released by striated muscle is undetermined. A comprehensive screen of binding sites of secreted MG53 will be needed to further understand how extracellular MG53 systemically inhibits insulin sensitivity. Whether the secretion of MG53 correlates with muscular contractions or exercise activity in vivo also remains to be defined.There are numerous studies showing muscle and heart as endocrine tissues that control systemic metabolism.10–14 The study by Wu et al6 provides evidence for the notion that myokines produced from diseased striated muscle could be pathological factors increasing systemic insulin resistance. This study provides proof-of-principle that the depletion of serum MG53 might potentially improve insulin sensitivity. Deciphering the mechanism of how MG53 impairs insulin signaling both intra- and extracellularly may provide new insights into the causes and treatment of insulin resistance and T2D.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.https://www.ahajournals.org/journal/circEric N. Olson, PhD, UT Southwestern Medical Center, Department of Molecular Biology, 6000 Harry Hines Blvd, Dallas, TX 75390-9148. Email eric.[email protected]eduReferences1. Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. Diabetes 2030: insights from yesterday, today, and future trends.Popul Health Manag. 2017; 20:6–12. doi: 10.1089/pop.2015.0181.CrossrefMedlineGoogle Scholar2. Thiebaud D, Jacot E, DeFronzo RA, Maeder E, Jequier E, Felber JP. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man.Diabetes. 1982; 31:957–963. doi: 10.2337/diacare.31.11.957CrossrefMedlineGoogle Scholar3. Shimano M, Ouchi N, Walsh K. Cardiokines: recent progress in elucidating the cardiac secretome.Circulation. 2012; 126:e327–e332. doi: 10.1161/CIRCULATIONAHA.112.150656LinkGoogle Scholar4. Eckardt K, Görgens SW, Raschke S, Eckel J. Myokines in insulin resistance and type 2 diabetes.Diabetologia. 2014; 57:1087–1099. doi: 10.1007/s00125-014-3224-xCrossrefMedlineGoogle Scholar5. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes.Diabetes Care. 2009; 32(suppl 2):S157–S163. doi: 10.2337/dc09-S302.CrossrefMedlineGoogle Scholar6. Wu HK, Zhang Y, Cao CM, Hu X, Fang M, Yao Y, Jin L, Chen G, Jiang P, Zhang S, Song R, Peng W, Liu F, Guo J, Tang L, He Y, Shan D, Huang J, Zhou Z, Wang DW, Lv F, Xiao RP. Glucose-sensitive myokine/cardiokine MG53 regulates systemic insulin response and metabolic homeostasis.Circulation. 2019; 139:901–914. doi: 10.1161/CIRCULATIONAHA.118.037216LinkGoogle Scholar7. Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, Ko JK, Lin P, Thornton A, Zhao X, Pan Z, Komazaki S, Brotto M, Takeshima H, Ma J. MG53 nucleates assembly of cell membrane repair machinery.Nat Cell Biol. 2009; 11:56–64. doi: 10.1038/ncb1812CrossrefMedlineGoogle Scholar8. Song R, Peng W, Zhang Y, Lv F, Wu HK, Guo J, Cao Y, Pi Y, Zhang X, Jin L, Zhang M, Jiang P, Liu F, Meng S, Zhang X, Jiang P, Cao CM, Xiao RP. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders.Nature. 2013; 494:375–379. doi: 10.1038/nature11834CrossrefMedlineGoogle Scholar9. Liu F, Song R, Feng Y, Guo J, Chen Y, Zhang Y, Chen T, Wang Y, Huang Y, Li CY, Cao C, Zhang Y, Hu X, Xiao RP. Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor α.Circulation. 2015; 131:795–804. doi: 10.1161/CIRCULATIONAHA.114.012285LinkGoogle Scholar10. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.Nature. 2012; 481:463–468. doi: 10.1038/nature10777CrossrefMedlineGoogle Scholar11. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K. FGF21 is an Akt-regulated myokine.FEBS Lett. 2008; 582:3805–3810. doi: 10.1016/j.febslet.2008.10.021CrossrefMedlineGoogle Scholar12. Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, Walsh K. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart.Circulation. 2008; 117:3099–3108. doi: 10.1161/CIRCULATIONAHA.108.767673LinkGoogle Scholar13. Amoasii L, Holland W, Sanchez-Ortiz E, Baskin KK, Pearson M, Burgess SC, Nelson BR, Bassel-Duby R, Olson EN. A MED13-dependent skeletal muscle gene program controls systemic glucose homeostasis and hepatic metabolism.Genes Dev. 2016; 30:434–446. doi: 10.1101/gad.273128.115CrossrefMedlineGoogle Scholar14. Grueter CE, van Rooij E, Johnson BA, DeLeon SM, Sutherland LB, Qi X, Gautron L, Elmquist JK, Bassel-Duby R, Olson EN. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13.Cell. 2012; 149:671–683. doi: 10.1016/j.cell.2012.03.029CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Wang Z, Li H, Wang H, Li X, Zhang Q, Wang H, Li K and Qiu Y (2022) TRIM72 exerts antitumor effects in breast cancer and modulates lactate production and MCT4 promoter activity by interacting with PPP3CA, Anti-Cancer Drugs, 10.1097/CAD.0000000000001304, 33:5, (489-501), Online publication date: 1-Jun-2022. Dong J, Zhou H, Li Y, Li R, Chen N, Zheng Y, Deng X, Luo M, Wu J and Wang L (2021) MG53 inhibits angiogenesis through regulating focal adhesion kinase signalling, Journal of Cellular and Molecular Medicine, 10.1111/jcmm.16777, 25:15, (7462-7471), Online publication date: 1-Aug-2021. Li X, Jiang M, Tan T, Narasimhulu C, Xiao Y, Hao H, Cui Y, Zhang J, Liu L, Yang C, Li Y, Ma J, Verfaillie C, Parthasarathy S, Zhu H and Liu Z (2019) N‐acetylcysteine prevents oxidized low‐density lipoprotein‐induced reduction of MG53 and enhances MG53 protective effect on bone marrow stem cells, Journal of Cellular and Molecular Medicine, 10.1111/jcmm.14798, 24:1, (886-898), Online publication date: 1-Jan-2020. Related articlesGlucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic HomeostasisHong-Kun Wu, et al. Circulation. 2019;139:901-914 February 12, 2019Vol 139, Issue 7 Advertisement Article InformationMetrics © 2019 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.118.038387PMID: 30742526 Originally publishedFebruary 11, 2019 Keywordsinsulin resistanceEditorialsdiabetes mellitus, type 2muscle, striatedPDF download Advertisement

MG53 and Disordered Metabolism in Striated Muscle.

MG53, biological function and potential as a therapeutic target

MG53 is a Double-Edged Sword for Human Diseases.

Glucose-sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis.

Upregulation of MG53 Induces Diabetic Cardiomyopathy Through Transcriptional Activation of Peroxisome Proliferation-Activated Receptor Α.

Cardiac effects and clinical applications of MG53

Friend or foe: the paradoxical roles of MG53 in diabetes mellitus

MG53/TRIM72: multi-organ repair protein and beyond

Prohibiting MG53 Phosphorylation Optimizes Its Therapeutic Potential in Diabetes.

Skeletal Muscle TRIB3 Mediates Glucose Toxicity in Diabetes and High- Fat Diet–Induced Insulin Resistance

Advances in the Study of MG53 in Cardiovascular Disease

MG53 is not a critical regulator of insulin signaling pathway in skeletal muscle

Blocking MG53S255 Phosphorylation Protects Diabetic Heart From Ischemic Injury

MG53 E3 Ligase–Dead Mutant Protects Diabetic Hearts From Acute Ischemic/Reperfusion Injury and Ameliorates Diet-Induced Cardiometabolic Damage

OR-010 the Potential Role of MG53 in Exercise-Mediated Modulation of Diabetic Cardiomyopathy in Db/db Mice

MG53’s non-physiologic interaction with insulin receptor: lack of effect on insulin-stimulated Akt phosphorylation in muscle, heart and liver tissues

MG53 Does Not Manifest the Development of Diabetes in db/db Mice

Secreted MG53 from Striated Muscle Impairs Systemic Insulin Sensitivity

MG53: A new protagonist in the precise treatment of cardiomyopathies

MG53 preserves mitochondrial integrity of cardiomyocytes during ischemia reperfusion-induced oxidative stress

Abstract 14197: C14a Mutation Abolishes Mg53-Aggravated Glucose Metabolic Dysfunction and Exerts a Dominant Therapeutic Target for Ischemia and Reperfusion (i/r) Injury in Diabetic Heart